Zobrazeno 1 - 10
of 36
pro vyhledávání: '"Guowen Yin"'
Publikováno v:
Biomedicines, Vol 12, Iss 9, p 2124 (2024)
Purpose: In the present study, we aimed to assess the effectiveness and safety of immune-targeted therapy (IT) with or without transarterial chemoembolization (TACE) for advanced hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT)
Externí odkaz:
https://doaj.org/article/15a38c3777e84abea021779562a8eb01
Publikováno v:
Cancer Medicine, Vol 12, Iss 10, Pp 11315-11333 (2023)
Abstract Background Although the appearance of portal vein tumor thrombus (PVTT) is significantly associated with unfavorable prognosis, there is insufficient evidence to confirm the efficacy and safety of the triple combination of transarterial chem
Externí odkaz:
https://doaj.org/article/3cfa2fc8405744f2b94a0fa1e2931e2b
Publikováno v:
Frontiers in Genetics, Vol 13 (2023)
Background: Transarterial chemoembolization (TACE) is the standard treatment option for intermediate-stage hepatocellular carcinoma (HCC), while response varies among patients. This study aimed to identify novel immune-related genes (IRGs) and establ
Externí odkaz:
https://doaj.org/article/a8d5989e4dc54ca48fec54835622dbf5
Autor:
Ran You, Yanjun Yang, Guowen Yin, Hao Jiang, Yousheng Lu, Liang Gui, Jun Bao, Qingyu Xu, Liang Feng
Publikováno v:
Pharmaceutics, Vol 15, Iss 7, p 1887 (2023)
Hepatocellular carcinoma (HCC) is a prevalent and high-mortality cancer worldwide, and its complexity necessitates novel strategies for drug selection and design. Current approaches primarily focus on reducing gene expression, while promoting gene ov
Externí odkaz:
https://doaj.org/article/4e1686df352d426d9a47aacdc4aac496
Autor:
Ran You, Qingyu Xu, Qi Wang, Qingqiao Zhang, Weizhong Zhou, Chi Cao, Xiangzhong Huang, Honghai Ji, Penghua Lv, Hao Jiang, You Lu, Yong Jin, Yongjun Li, Long Cheng, Weidong Wang, Hao Xu, Xiaoli Zhu, Guowen Yin
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
ObjectiveCamrelizumab is a newly developed program-death receptor one inhibitor; the real-world evidence about its application in hepatocellular carcinoma (HCC) treatment is lacking. Therefore, this prospective, multi-center, real-world study evaluat
Externí odkaz:
https://doaj.org/article/1065ec3626f348e0b22ba5a711c4ca99
Publikováno v:
Advances in Therapy. 40:1686-1704
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8875ca474f71b1d67788821bb5f773b7
https://doi.org/10.1007/s12325-023-02449-6
https://doi.org/10.1007/s12325-023-02449-6
Autor:
Feng, Ran You, Yanjun Yang, Guowen Yin, Hao Jiang, Yousheng Lu, Liang Gui, Jun Bao, Qingyu Xu, Liang
Publikováno v:
Pharmaceutics; Volume 15; Issue 7; Pages: 1887
Hepatocellular carcinoma (HCC) is a prevalent and high-mortality cancer worldwide, and its complexity necessitates novel strategies for drug selection and design. Current approaches primarily focus on reducing gene expression, while promoting gene ov
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=multidiscipl::2375979eb15ae44385ac1bca68e57272
Autor:
Quanren Wang, Shuni Wang, Xiao Zhang, Guowen Yin, Enxiao Li, Zujiang Yu, Xinmin Zhou, Kuansheng Ma, Zhanyu Pan, Xi Chen, Kangsheng Gu, Zhiming Wang, Xiaoming Chen, Lequn Li, Jiayin Yang, Ling Zhang, Xianhai Mao, Jianping Xiong, Zhenggang Ren, Jingfeng Liu, Tao Yin, Li Xu, Yanqiao Zhang, Guoliang Shao, Jian Wu, Lihua Wu, Yun Zhang, Shanzhi Gu, Jie Shen, Jianming Xu
Purpose:We assessed the efficacy and safety of camrelizumab [an anti-programmed death (PD-1) mAb] plus apatinib (a VEGFR-2 tyrosine kinase inhibitor) in patients with advanced hepatocellular carcinoma (HCC).Patients and Methods:This nonrandomized, op
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c896809f821cea052765763557d4de46
https://doi.org/10.1158/1078-0432.c.6530222.v1
https://doi.org/10.1158/1078-0432.c.6530222.v1
Autor:
Quanren Wang, Shuni Wang, Xiao Zhang, Guowen Yin, Enxiao Li, Zujiang Yu, Xinmin Zhou, Kuansheng Ma, Zhanyu Pan, Xi Chen, Kangsheng Gu, Zhiming Wang, Xiaoming Chen, Lequn Li, Jiayin Yang, Ling Zhang, Xianhai Mao, Jianping Xiong, Zhenggang Ren, Jingfeng Liu, Tao Yin, Li Xu, Yanqiao Zhang, Guoliang Shao, Jian Wu, Lihua Wu, Yun Zhang, Shanzhi Gu, Jie Shen, Jianming Xu
Supplementary Methods, Supplementary Figure S1-4, Supplementary Table S1-8
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bd5ad80e3eb618e473ad306b9053d36c
https://doi.org/10.1158/1078-0432.22479434
https://doi.org/10.1158/1078-0432.22479434
Autor:
Chengyou Du, Guoliang Shao, Yajin Chen, Yabing Guo, Jianbing Wu, Aibing Xu, Yuxian Bai, Ming Huang, Baocai Xing, Bixiang Zhang, Tao Yin, Yong Yang, Yan Wang, Yilei Mao, Xuetao Shi, Mingxia Chen, Yinying Lu, Weidong Jia, Zhenggang Ren, Jiuwei Cui, Zhenyuan Gao, Chao Liu, Wei Yang, Yunfeng Shan, Shanzhi Gu, Zhendong Chen, Qiu Li, Yanru Qin, Guowen Yin, Jianming Xu, Jian Wu, Shundong Cang, Feng Xia, Baorui Liu, Junye Wang, Jinhai Wang, Gao-Jun Teng, Hui Zhou, Jia Fan, Zhiqiang Meng
Publikováno v:
The Lancet Oncology. 22:977-990
Summary Background China has a high burden of hepatocellular carcinoma, and hepatitis B virus (HBV) infection is the main causative factor. Patients with hepatocellular carcinoma have a poor prognosis and a substantial unmet clinical need. The phase
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e8314c4699b73c133f12cb36181eec56
https://doi.org/10.1016/s1470-2045(21)00252-7
https://doi.org/10.1016/s1470-2045(21)00252-7